Replies to post #13396 on Momenta Pharmaceuticals, Inc. (MNTA)

[Double_Bagel]

Now that MNTA has two approved products doesn't it deserve a much higher valuation than say CHRS which doesn't have any approved drugs yet.

http://www.coherus.com/corporate-performance/

Right now MNTA only has a Market cap of about $150-200 million higher than MNTA. A few months ago CHRS had a much higher market cap than MNTA.

http://finance.yahoo.com/echarts?s=MNTA+Interactive#%7B%22range%22%3A%22ytd%22%2C%22scale%22%3A%22linear%22%2C%22comparisons%22%3A%7B%22CHRS%22%3A%7B%22color%22%3A%22%23cc0000%22%2C%22weight%22%3A1%7D%7D%7D

What was the reason for CHRS to shoot up from $15 to $33 earlier this year? Couldn't the same reasons (for why it shot up) apply to MNTA now and more so with an approved drug?

Also, is EPRS worth looking into at this low Market cap?

Thanks.

[DewDiligence]

why beat around the bush about it? Why didn't Craig just come out and plainly state what you are surmising? I don't see the upside in not being direct.

In matters relating to litigation, the less you say in public, the better.

…regarding my point in the previous post, does it have any merit…?

Yes, absolutely. The FDA understands that the disclosures it made with respect to the approval of MNTA’s generic Lovenox were injudicious, and that mistake won’t be repeated.